Ascendis Pharma A/S (NASDAQ:ASND) Sees Large Volume Increase

Ascendis Pharma A/S (NASDAQ:ASND) shares saw unusually-high trading volume on Thursday . Approximately 616,993 shares were traded during mid-day trading, an increase of 53% from the previous session’s volume of 402,361 shares.The stock last traded at $113.95 and had previously closed at $112.93.

Analyst Upgrades and Downgrades

ASND has been the subject of several analyst reports. Oppenheimer raised Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a report on Thursday, September 5th. Cantor Fitzgerald reduced their price objective on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. TD Cowen dropped their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $187.08.

Ascendis Pharma A/S Price Performance

The company has a market capitalization of $6.94 billion, a P/E ratio of -12.41 and a beta of 0.63. The company has a fifty day moving average price of $132.45 and a two-hundred day moving average price of $136.73.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently modified their holdings of the business. Vestal Point Capital LP bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $78,719,000. Price T Rowe Associates Inc. MD increased its position in shares of Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares during the period. Acadian Asset Management LLC raised its stake in Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares during the period. Finally, Westfield Capital Management Co. LP boosted its position in Ascendis Pharma A/S by 6.0% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock valued at $507,658,000 after acquiring an additional 228,457 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.